Leap Therapeutics, Inc. (NASDAQ:LPTX) has earned an average broker rating score of 1.50 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One research analyst has rated the stock with a buy rating and one has issued a strong buy rating on the company.

Brokers have set a 12 month consensus price target of $15.50 for the company, according to Zacks. Zacks has also given Leap Therapeutics an industry rank of 99 out of 265 based on the ratings given to its competitors.

Separately, Zacks Investment Research raised shares of Leap Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 6th.

TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Set $15.50 Price Target for Leap Therapeutics, Inc. (LPTX)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/29/zacks-analysts-set-15-50-price-target-for-leap-therapeutics-inc-lptx.html.

Shares of Leap Therapeutics (NASDAQ:LPTX) traded up 0.3580% on Tuesday, reaching $5.9713. 6,282 shares of the company were exchanged. Leap Therapeutics has a 12-month low of $5.40 and a 12-month high of $10.10. The stock’s market capitalization is $56.10 million. The firm has a 50 day moving average price of $6.61 and a 200-day moving average price of $7.20.

Leap Therapeutics (NASDAQ:LPTX) last posted its quarterly earnings results on Friday, August 11th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by $0.03. On average, analysts predict that Leap Therapeutics will post ($3.16) EPS for the current fiscal year.

An institutional investor recently bought a new position in Leap Therapeutics stock. Renaissance Technologies LLC acquired a new position in Leap Therapeutics, Inc. (NASDAQ:LPTX) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 45,445 shares of the company’s stock, valued at approximately $417,000. Renaissance Technologies LLC owned 0.48% of Leap Therapeutics as of its most recent SEC filing. 0.81% of the stock is owned by hedge funds and other institutional investors.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).

Get a free copy of the Zacks research report on Leap Therapeutics (LPTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Leap Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics Inc. and related stocks with our FREE daily email newsletter.